Asis Palazon
CEO/CSO Adaptam Therapeutics
Seminars
Monday 8th June 2026
Fireside Chat: How Can We Predict Clinical Reality Through Preclinical Models & Translational Strategies?
12:30 pm
- Which preclinical models have proven most predictive for bispecifics, TCEs, and ADCs- including safety and immunogenicity risk, and which consistently fail to translate?
- How do teams combine in vitro, in vivo, and computational approaches to reduce uncertainty before first-in-human studies?
- What translational signals provide sufficient confidence to advance a program, and how do teams actively manage remaining risk?
Tuesday 7th July 2026
Engineering Bispecifics for Solid Tumour Success to Maximise Penetration, Immune Engagement & Translational Impact
9:00 am
Solid tumours represent the next major frontier for bispecific antibody therapeutics, with significant unmet medical need and opportunities to expand efficacy beyond hematologic malignancies. This workshop will explore strategies to overcome the unique challenges of solid tumours, including physical barriers, heterogeneous target expression, and an immunosuppressive tumour microenvironment. Participants will learn to optimise tumour penetration, enhance immune engagement, and leverage preclinical models to anticipate clinical outcomes and accelerate the path from discovery to clinic.
This workshop will gather experts to discuss:
- Understand key barriers to efficacy and learn how physical and immunological features of solid tumours impact bispecific performance
- Enhance tumour penetration and activity by applying cutting-edge engineering strategies and combination approaches to maximise therapeutic impact
- Leverage hematologic learnings for solid tumours and translate proven principles from blood cancer bispecifics to inform solid tumour design
- Predict clinical success with preclinical tools by evaluating models and predictive strategies to anticipate efficacy, optimise dosing, and reduce translational risk
